Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study.

COVID-19 cancer hematological malignancies intensive care unit solid tumors

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 19 01 2022
accepted: 16 02 2022
entrez: 1 4 2022
pubmed: 2 4 2022
medline: 2 4 2022
Statut: epublish

Résumé

Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce. We aimed to investigate the association between active cancer and mortality among patients requiring organ support in the ICU. In this ambispective study encompassing 17 hospitals in France, we included all adult active cancer patients with SARS-CoV-2 infection requiring organ support and admitted in ICU. For each cancer patient, we included 3 non cancer patients as controls. Patients were matched at the same ratio using the inverse probability weighting approach based on a propensity score assessing the probability of cancer at admission. Mortality at day 60 after ICU admission was compared between cancer patients and non-cancer patients using primary logistic regression analysis and secondary multivariable analyses. Between March 12, 2020 and March 8, 2021, 2608 patients were admitted with SARS-CoV-2 infection in our study, accounting for 2.8% of the total population of patients with SARS-CoV-2 admitted in all French ICUs within the same period. Among them, 105 (n=4%) presented with cancer (51 patients had hematological malignancy and 54 patients had solid tumors). 409 of 420 patients were included in the propensity score matching process, of whom 307 patients in the non-cancer group and 102 patients in the cancer group. 145 patients (35%) died in the ICU at day 60, 59 (56%) with cancer and 86 (27%) without cancer. In the primary logistic regression analysis, the odds ratio for death associated to cancer was 2.3 (95%CI 1.24 - 4.28, p=0.0082) higher for cancer patients than for a non-cancer patient at ICU admission. Exploratory multivariable analyses showed that solid tumor (OR: 2.344 (0.87-6.31), p=0.062) and hematological malignancies (OR: 4.144 (1.24-13.83), p=0.062) were independently associated with mortality. Patients with cancer and requiring ICU admission for SARS-CoV-2 infection had an increased mortality, hematological malignancy harboring the higher risk in comparison to solid tumors.

Sections du résumé

Background UNASSIGNED
Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce.
Research Question UNASSIGNED
We aimed to investigate the association between active cancer and mortality among patients requiring organ support in the ICU.
Study Design and Methods UNASSIGNED
In this ambispective study encompassing 17 hospitals in France, we included all adult active cancer patients with SARS-CoV-2 infection requiring organ support and admitted in ICU. For each cancer patient, we included 3 non cancer patients as controls. Patients were matched at the same ratio using the inverse probability weighting approach based on a propensity score assessing the probability of cancer at admission. Mortality at day 60 after ICU admission was compared between cancer patients and non-cancer patients using primary logistic regression analysis and secondary multivariable analyses.
Results UNASSIGNED
Between March 12, 2020 and March 8, 2021, 2608 patients were admitted with SARS-CoV-2 infection in our study, accounting for 2.8% of the total population of patients with SARS-CoV-2 admitted in all French ICUs within the same period. Among them, 105 (n=4%) presented with cancer (51 patients had hematological malignancy and 54 patients had solid tumors). 409 of 420 patients were included in the propensity score matching process, of whom 307 patients in the non-cancer group and 102 patients in the cancer group. 145 patients (35%) died in the ICU at day 60, 59 (56%) with cancer and 86 (27%) without cancer. In the primary logistic regression analysis, the odds ratio for death associated to cancer was 2.3 (95%CI 1.24 - 4.28, p=0.0082) higher for cancer patients than for a non-cancer patient at ICU admission. Exploratory multivariable analyses showed that solid tumor (OR: 2.344 (0.87-6.31), p=0.062) and hematological malignancies (OR: 4.144 (1.24-13.83), p=0.062) were independently associated with mortality.
Interpretation UNASSIGNED
Patients with cancer and requiring ICU admission for SARS-CoV-2 infection had an increased mortality, hematological malignancy harboring the higher risk in comparison to solid tumors.

Identifiants

pubmed: 35359407
doi: 10.3389/fonc.2022.858276
pmc: PMC8960921
doi:

Types de publication

Journal Article

Langues

eng

Pagination

858276

Informations de copyright

Copyright © 2022 Plais, Labruyère, Creutin, Nay, Plantefeve, Tapponnier, Jonas, Ngapmen, Le Guennec, De Roquetaillade, Argaud, Jamme, Goulenok, Merouani, Leclerc, Sauneuf, Shidasp, Stoclin, Bardet, Mir, Ibrahimi and Llitjos.

Déclaration de conflit d'intérêts

AB declare consulting fees for ROCHE SAS. J-FL is employed by bioMérieux but was employed by Institut Gustave Roussy when that study was performed. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
PLoS One. 2021 Mar 25;16(3):e0249038
pubmed: 33765049
Lancet Oncol. 2009 Jun;10(6):589-97
pubmed: 19482247
Ann Intensive Care. 2021 Aug 19;11(1):127
pubmed: 34410543
J Thromb Haemost. 2020 Sep;18(9):2349-2357
pubmed: 32692862
Crit Care. 2021 Jun 30;25(1):224
pubmed: 34193220
Cancer Cell. 2021 Feb 8;39(2):257-275.e6
pubmed: 33476581
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
J Infect. 2020 Aug;81(2):e124-e125
pubmed: 32474041
Chest. 2020 Nov;158(5):2130-2135
pubmed: 32710891
JCO Glob Oncol. 2021 Aug;7:1286-1305
pubmed: 34406802
Acta Oncol. 2012 Sep;51(7):897-905
pubmed: 22548367
J Clin Oncol. 2020 Nov 20;38(33):3914-3924
pubmed: 32986528
Blood Adv. 2020 Dec 8;4(23):5966-5975
pubmed: 33278301
J Mark Access Health Policy. 2021 Nov 11;9(1):2002008
pubmed: 34790342
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Intensive Care Med. 2019 Jul;45(7):977-987
pubmed: 31143998
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Crit Care Med. 2010 Jan;38(1):9-15
pubmed: 19829101
Crit Care. 2009;13(1):R15
pubmed: 19200368
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Transbound Emerg Dis. 2021 Mar;68(2):213-215
pubmed: 32892500
Front Oncol. 2021 Mar 25;11:652535
pubmed: 33842366
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Eur Respir Rev. 2019 Mar 27;28(151):
pubmed: 30918022
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
Ann Intensive Care. 2021 Jan 29;11(1):20
pubmed: 33512602
BMJ. 2020 May 22;369:m1985
pubmed: 32444460

Auteurs

Henri Plais (H)

Intensive Care Unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Marie Labruyère (M)

Department of Intensive Care, Dijon Bourgogne University Hospital, Dijon, France.

Thibault Creutin (T)

Service de Médecine Intensive and Réanimation, APHP-CUP, Hôpital Cochin, Paris, France.

Paula Nay (P)

Medical Intensive Care Unit, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.

Gaëtan Plantefeve (G)

Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil, France.

Romain Tapponnier (R)

Medical Intensive Care Unit, Hôpital Jean Minjoz Hospital, Besançon, France.

Maud Jonas (M)

Centre Hospitalier Général de Saint-Nazaire, Service de Médecine Intensive Réanimation, Saint-Nazaire, France.

Nadege Tchikangoua Ngapmen (NT)

Intensive Care Unit, Centre Hospitalier de Château-Thierry, Château-Thierry, France.

Loïc Le Guennec (L)

Médecine Intensive Réanimation Neurologique, Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Charles De Roquetaillade (C)

Department of Anesthesiology and Critical Care, Hôpital Lariboisière, FHU PROMICE, DMU Parabol, APHP, Paris, France.

Laurent Argaud (L)

Medical ICU, Edouard Herriot University Hospital, Lyon, France.

Matthieu Jamme (M)

Intensive Care Unit, Poissy-Saint-Germain-en-Laye Hospital, Poissy, France.

Cyril Goulenok (C)

Medical-Surgical Intensive Care Unit, Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, Massy, France.

Karim Merouani (K)

Medical and Surgical Intensive Care Unit, Alençon Hospital, Alençon, France.

Maxime Leclerc (M)

Intensive Care Unit, Centre Hospitalier Mémorial France Etats-Unis, Saint-Lô, France.

Bertrand Sauneuf (B)

Réanimation - Médecine Intensive, Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France.

Sami Shidasp (S)

Intensive Care Unit, Etampes Hospital, Etampes, France.

Annabelle Stoclin (A)

Intensive Care Unit, Centre Hospitalier de Château-Thierry, Château-Thierry, France.

Aurélie Bardet (A)

Bureau of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France and U1018 INSERM Oncostat, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.

Olivier Mir (O)

Gustave-Roussy, Département d'oncologie Médicale, Villejuif, France.

Nusaibah Ibrahimi (N)

Bureau of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France and U1018 INSERM Oncostat, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.

Jean-François Llitjos (JF)

Intensive Care Unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Classifications MeSH